Purpose To assess eslicarbazepine acetate (ESL) in patients included in the Eslicarbazepine acetate in Partial-Onset Seizures (EPOS) study who had previously not responded to carbamazepine (CBZ) treatment.
Method EPOS was a prospective, non-interventional study, conducted under everyday clinical practice conditions in adult patients with uncontrolled partial-onset seizures receiving antiepileptic monotherapy, whose clinician had previously and independently decided to initiate ESL add-on therapy. A post hoc analysis was conducted in those with a documented non-response to historic CBZ treatment. Assessments included retention, responder and seizure freedom rates, Quality of Life in Epilepsy Inventory-10 (QOLIE-10) score, and safety/tolerability.
Results Forty-five patients had documented non-response to CBZ. Two patients discontinued ESL due to AEs and one due to lack of efficacy. After 6 months, retention, responder and seizure freedom rates (with 95% confidence intervals) were 88.9% (75.9–96.3%; n=45), 95.1% (83.5–99.4%; n=41) and 33.3% (19.6–49.5%; n=42), respectively. Mean QOLIE-10 total score decreased from 2.8 (n=21) at baseline to 2.2 (−13.0%; n=18) after 6 months. Two adverse events were reported for two patients (both hyponatremia).
Conclusion ESL was effective and well tolerated as add-on to antiepileptic monotherapy in patients with documented non-response to CBZ treatment in a real-world setting.
Supported by Eisai.